Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Revenue Per Share for the year ending December 31, 2023: USD 0.00

Eliem Therapeutics Inc Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Eliem Therapeutics Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Eliem Therapeutics Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Eliem Therapeutics Inc Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Eliem Therapeutics Inc Revenue Per Share for the year ending December 31, 2019 was USD 0.00.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends